BPA-FLECAINIDE (Beximco Pharmaceuticals Australia Pty Ltd)

BPA-FLECAINIDE (tablets) is indicated for:

Supraventricular arrhythmias:

• due to pre-excitation syndromes, e.g. Wolff-Parkinson-White and Lown-Ganong-Levine syndromes
• due to dual AV nodal pathways in patients with debilitating symptoms
• paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms

Although BPA-FLECAINIDE may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. In these patients, particularly in the presence of impaired left ventricular function, BPA-FLECAINIDE should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.

Use of BPA-FLECAINIDE in chronic atrial fibrillation has not been adequately studied and is not recommended.

Life threatening ventricular arrhythmias not controlled by other drugs.

BPA-FLECAINIDE tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.

Prescribers should also consult the 'Special Warnings and Precautions for Use' section of this Product Information.